A Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (DSW)
Latest Information Update: 12 Oct 2021
At a glance
- Drugs TWB 103 (Primary)
- Indications Wounds
- Focus Adverse reactions; Therapeutic Use
- Sponsors Transwell Biotech
Most Recent Events
- 04 Oct 2021 Status changed from recruiting to completed.
- 07 Apr 2021 New trial record